HopeStage
Back to all studies
CompletedNCT02493777

HLD200 for ADHD Symptoms in Children Ages 6 to 12

About this titleRead the official source — NCT02493777
Medication studyAges 6–12United States
The study in practice

Understand this study

Who was this study for?

Listed age limits: 6 years to 12 years.

Listed locations
Newport Beach and 6 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJuly 2015
Recruitment status
Completed
Enrollment listed in the registry
125
Sponsor
Ironshore Pharmaceuticals and Development, Inc
Sponsor type
Other organization
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 6 Years to 12 Years
Official registry ID
NCT02493777
Official title
Show the full official title

Ph 3 Multicenter OL Treatment-optimized RDBPC Forced-withdrawal, Parallel Grp Study to Evaluate Safety & Efficacy of Evening Dosed HLD200, a Novel DR/ER Formulation (DELEXIS) of MPH HCl in Children Aged 6-12 With ADHD in Classroom Setting

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Newport Beach · Bradenton · Maitland

4 more locations
  • Marshfield
  • Las Vegas
  • Houston
  • Lubbock

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Ironshore Pharmaceuticals and Development, Inc.

Did this study involve medication?

Yes. The study involved medication, including HLD200 methylphenidate hydrochloride (MPH) Capsules and Placebo.

Who was this study for?

Listed age limits: 6 years to 12 years.

Want to explore more studies?

Explore studies